Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchang
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... WILSONVILLE, Ore. , Aug. 29, 2014 /PRNewswire-iReach/ ... its Accessory (Axilla) Strap for the SAM Junctional ... SAM Medical Products announced ... a voluntary recall to address a potential issue ... strap used for the Axilla application of the ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... 11, 2012  Stiefel, a GSK (NYSE: GSK ) company, ... the New Drug Application for Fabior (tazarotene) Foam, 0.1%. ... formulation for the treatment of acne vulgaris in patients 12 years ... meeting the needs of patients and dermatologists and we believe ...
... 11, 2012  To broaden their marketing reach, biopharmaceutical ... tactics to engage key customer groups such as ... leaders. But as they shift to activities such ... and other approaches, marketing groups are facing questions ...
Cached Medicine Technology:Stiefel receives US FDA approval of Fabior™ Foam, 0.1% 2Stiefel receives US FDA approval of Fabior™ Foam, 0.1% 3New Report Outlines Use of Innovative Marketing to Engage Customer Groups that are Key to the Pharmaceutical Industry 2
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) ... September, where issues related to claims involving the pain ... Pennsylvania, Bernstein Liebhard LLP reports. , According to ... website, the meeting is scheduled to take place on ... latest of several Tylenol conferences that have taken place ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many ... suppliers carefully, Top10BestSEOHosting.com is here to announce that ... hosting suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ... top-of-the-line shared hosting plan. The company’s approach to ... is affordable, accessible and powerful enough for anyone ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
(Date:9/1/2014)... CA (PRWEB) September 01, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... The US FDA announced on August 28, that specific ... recalled (Class I) as the device may reverse ... DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an implant ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... but not frequency, study suggests , , THURSDAY, April ... 2-year-olds relate to each other affects the quality -- ... "terrible twos." And a child,s temperament plays a role ... to a new study. , Interactions between 60 mothers ...
... 3, 2008 With spring here and,summer fast approaching, ... said, attractive feet are a MUST!, YogaToes(R) are ... feel great. YogaToes(R) beautify feet with passive exercise that,helps ... by tight,shoes, high heels and overexertion., "Women aren,t ...
... MedQuist,Inc. (Pink Sheets: MEDQ.PK) announces that ... hospital in Newburyport, Mass., has selected MedQuist,Technology ... solution,including dictation, transcription and speech recognition. Anna ... and is home to a,nationally recognized Wound ...
... Third Bank,today announced a strategic alliance with GHN-Online ... cycle management services to,the healthcare industry, that will ... healthcare providers. The alliance,will enable Fifth Third Bank ... to payments -- and integrate the data into ...
... Expands Global Product Potential, LEXINGTON, Mass., April ... ) today announced the signing of a,License, Supply ... rights to market VANTAS(R) (histrelin acetate subcutaneous,implant) throughout ... is a,12-month implant for the treatment of advanced ...
... a child for a lifetime, researchers say, , , THURSDAY, April ... United States were victims of maltreatment in 2006 during their ... or neglect during their first week of life, federal officials ... examination of the risk for nonfatal maltreatment of children less ...
Cached Medicine News:Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:New Ten-Minute Foot Exercisers Beautify Feet for Spring and Summer Sandal Season 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 3Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 2Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: